Grifols (GIKLY) Cost of Revenue (2011 - 2020)
Grifols (GIKLY) reported Cost of Revenue of $775.1 million for Q1 2020, up 8.46% on a YoY basis from $714.6 million in Q2 2019, and down 65.08% quarter-over-quarter from $2.2 billion in Q4 2019.
Grifols (GIKLY) Cost of Revenue (2011 - 2020) Analysis & Trends
Grifols has reported Cost of Revenue for 9 years, with the latest figure at $775.1 million in Q1 2020.
- For the quarter ending Q1 2020, Cost of Revenue rose 8.46% year-over-year to $775.1 million; the trailing twelve-month figure through Mar 2020 stood at $5.7 billion (up 40.75% YoY), and the FY2025 full-year result was $5.4 billion, up 15.02% from the prior year.
- Cost of Revenue for Q1 2020 stood at $775.1 million, down from $2.2 billion in the prior quarter.
- The five-year high for Cost of Revenue was $2.2 billion in Q4 2019, with the low at $553.8 million in Q1 2017.
- Historically, Cost of Revenue has averaged $995.6 million across 5 years, with a median of $674.0 million in 2018.
- The largest YoY upside for Cost of Revenue was 603.89% in 2016 against a maximum downside of 3.94% in 2016.
- Grifols' Cost of Revenue stood at $643.1 million in 2016, then jumped by 195.8% to $1.9 billion in 2017, then advanced by 3.94% to $2.0 billion in 2018, then rose by 12.25% to $2.2 billion in 2019, then sank by 65.08% to $775.1 million in 2020.
- The last three Cost of Revenue figures came in at $775.1 million (Q1 2020), $2.2 billion (Q4 2019), and $714.6 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 2.53 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 3.58 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 8.11 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 4.22 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 4.20 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 2.74 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.45 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 3.55 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 3.42 Bn |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 775.06 Mn |
| Mar 31, 2020 | 775.06 Mn |
| Dec 31, 2019 | 2.22 Bn |
| Dec 31, 2019 | 2.22 Bn |
| Mar 31, 2019 | 714.63 Mn |
| Mar 31, 2019 | 714.63 Mn |
| Dec 31, 2018 | 1.98 Bn |
| Dec 31, 2018 | 1.98 Bn |
| Jun 30, 2018 | 691.82 Mn |
| Jun 30, 2018 | 691.82 Mn |
| Mar 31, 2018 | 656.26 Mn |
| Mar 31, 2018 | 656.26 Mn |
| Dec 31, 2017 | 1.90 Bn |
| Dec 31, 2017 | 1.90 Bn |
| Jun 30, 2017 | 626.15 Mn |
| Jun 30, 2017 | 626.15 Mn |
| Mar 31, 2017 | 553.78 Mn |
| Mar 31, 2017 | 553.78 Mn |
| Dec 31, 2016 | 643.10 Mn |
| Dec 31, 2016 | 643.10 Mn |